Author

A. Leuzzi

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:benchmarking· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Assay:imaging· 2 Organism:non-human primate· 2 Assay:proteomics· 2 Organism:mouse· 1

Frequent Co-Authors

A. Folgori· 2 shared A. Vitelli· 2 shared S. Capone· 2 shared S. Colloca· 2 shared A. C. M. Boon· 1 shared A. Cook· 1 shared A. Dodson· 1 shared A. Lahm· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. Folgori

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Durable immunity to SARS-CoV-2 in both lower and upper airways achieved with a gorilla adenovirus (GRAd) S-2P vaccine in non-human primates

J. I. Moliva, S. F. Andrew, B. J. Flynn, D. A. Wagner, K. E. Foulds, M. Gagne, D. R. Flebbe, E. Lamb, S. Provost, J. Marquez, A. Mychalowych, C. Lorag, C. C. Honeycutt, M. R. Burnett, L. McCormick, , Nason

This study shows a gorilla adenovirus-based vaccine provides durable immunity against SARS-CoV-2 in both airways of non-human primates, with enhanced protection from aerosol delivery and prime-boost regimens.

bioRxiv · Nov 22, 2023 · PreprintImmunology

Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19

A. Vitelli, S. Capone, A. Raggioli, M. Gentile, S. Battella, A. Lahm, A. Sommella, A. M. Contino, R. A. Urbanowicz, R. Scala, F. Barra, A. Leuzzi, E. Lilli, G. Miselli, A. Noto, , S. Colloca

This paper evaluates a gorilla adenovirus vaccine candidate for COVID-19, showing it is immunogenic in mice and macaques and supports its advancement to a Phase I clinical trial.

bioRxiv · Oct 22, 2020Immunology